Related Experiment Video
Updated: Aug 14, 2025
Coculture Assays to Study Macrophage and Microglia Stimulation of Glioblastoma Invasion
Published on: October 20, 2016
Interaction of glioma-associated microglia/macrophages and anti-PD1 immunotherapy
Chunhua Wang1,2,3, Quan Chen1,3, Meiqing Chen1,2
1Institute of Immunotherapy, Fujian Medical University, No. 1, Xuefu North Road, Minhou County, Fuzhou, 350122, Fujian, People's Republic of China.
Abstract:
Anti-PD-1-based therapy has resulted in a minimal clinical response in malignant gliomas. Gliomas contain numerous glioma-associated microglia/macrophages (GAMs), reported to contribute to an immunosuppressive microenvironment and promote glioma progression. However, whether and how GAMs affect anti-PD-1 immunotherapy in glioma remains unclear. Here, we demonstrated that M1-like GAMs contribute to the anti-PD-1 therapeutic response, while the accumulation of M2-like GAMs is associated with therapeutic resistance. Furthermore, we found that PD-L1 ablation reverses GAMs M2-like phenotype and is beneficial to anti-PD-1 therapy. We also demonstrated that tumor-induced impairment of the antigen-presenting function of GAMs could limit the antitumor immunity of CD4+ T cells in anti-PD-1 therapy. Our study highlights the impact of GAMs activation on anti-PD-1 treatment and provides new insights into the role of GAMs in regulating anti-PD-1 therapy in gliomas.
Insights
Malignant glioma treatment with anti-PD-1 therapy is improved by M1-like glioma-associated microglia/macrophages (GAMs). M2-like GAMs hinder response, but PD-L1 ablation can reverse this, enhancing immunotherapy effectiveness.
Area of Science:
- Neuro-oncology
- Immunology
- Cancer research
Background:
- Malignant gliomas exhibit minimal response to anti-PD-1 therapy.
- Glioma-associated microglia/macrophages (GAMs) create an immunosuppressive tumor microenvironment, promoting glioma progression.
- The precise role of GAMs in anti-PD-1 immunotherapy for gliomas is not fully understood.
Purpose of the Study:
- To investigate the role of GAMs phenotypes in anti-PD-1 therapy response in malignant gliomas.
- To determine if PD-L1 modulation of GAMs impacts immunotherapy outcomes.
- To elucidate how GAMs influence anti-tumor immunity mediated by CD4+ T cells during anti-PD-1 treatment.
Main Methods:
- Phenotypic analysis of glioma-associated microglia/macrophages (GAMs) in relation to anti-PD-1 therapy response.
- Assessment of PD-L1 expression and its effect on GAMs phenotype and therapeutic outcomes.
- Evaluation of GAMs' antigen-presenting function and its impact on CD4+ T cell-mediated anti-tumor immunity.
Main Results:
- M1-like GAMs are associated with a positive response to anti-PD-1 therapy.
- Accumulation of M2-like GAMs correlates with resistance to anti-PD-1 therapy.
- PD-L1 ablation effectively reverses the M2-like GAM phenotype, enhancing anti-PD-1 therapy efficacy.
- Tumor-induced dysfunction in GAMs' antigen-presenting capacity limits CD4+ T cell anti-tumor immunity.
Conclusions:
- GAM activation status significantly impacts the effectiveness of anti-PD-1 treatment in gliomas.
- Targeting GAM phenotypes, particularly by modulating PD-L1, offers a promising strategy to improve anti-PD-1 immunotherapy for malignant gliomas.
- Understanding GAMs' role in regulating anti-tumor immunity is crucial for developing novel therapeutic approaches in neuro-oncology.
